Next Article in Journal
Use of a Novel Peptide Welding Technology Platform for the Development of B- and T-Cell Epitope-Based Vaccines
Next Article in Special Issue
Type II NKT Cell Agonist, Sulfatide, Is an Effective Adjuvant for Oral Heat-Killed Cholera Vaccines
Previous Article in Journal
Long-Term Follow-Up of Mesothelioma Patients Treated with Dendritic Cell Therapy in Three Phase I/II Trials
Previous Article in Special Issue
Advances in Oral Subunit Vaccine Design
Review

Delivery Routes for COVID-19 Vaccines

Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon 34141, Korea
*
Author to whom correspondence should be addressed.
Academic Editor: Bert Devriendt
Vaccines 2021, 9(5), 524; https://doi.org/10.3390/vaccines9050524
Received: 15 April 2021 / Revised: 12 May 2021 / Accepted: 17 May 2021 / Published: 19 May 2021
(This article belongs to the Special Issue Recent Advances in Mucosal Vaccines)
The novel coronavirus, SARS-CoV-2, which causes COVID-19, has resulted in a pandemic with millions of deaths. To eradicate SARS-CoV-2 and prevent further infections, many vaccine candidates have been developed. These vaccines include not only traditional subunit vaccines and attenuated or inactivated viral vaccines but also nucleic acid and viral vector vaccines. In contrast to the diversity in the platform technology, the delivery of vaccines is limited to intramuscular vaccination. Although intramuscular vaccination is safe and effective, mucosal vaccination could improve the local immune responses that block the spread of pathogens. However, a lack of understanding of mucosal immunity combined with the urgent need for a COVID-19 vaccine has resulted in only intramuscular vaccinations. In this review, we summarize the history of vaccines, current progress in COVID-19 vaccine technology, and the status of intranasal COVID-19 vaccines. Future research should determine the most effective route for vaccine delivery based on the platform and determine the mechanisms that underlie the efficacy of different delivery routes. View Full-Text
Keywords: COVID-19; SARS-CoV-2; vaccine; mucosal vaccine COVID-19; SARS-CoV-2; vaccine; mucosal vaccine
Show Figures

Figure 1

MDPI and ACS Style

Park, J.H.; Lee, H.K. Delivery Routes for COVID-19 Vaccines. Vaccines 2021, 9, 524. https://doi.org/10.3390/vaccines9050524

AMA Style

Park JH, Lee HK. Delivery Routes for COVID-19 Vaccines. Vaccines. 2021; 9(5):524. https://doi.org/10.3390/vaccines9050524

Chicago/Turabian Style

Park, Jang H., and Heung K. Lee 2021. "Delivery Routes for COVID-19 Vaccines" Vaccines 9, no. 5: 524. https://doi.org/10.3390/vaccines9050524

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop